Insiders · ELVN

ELVN insider transactions

Enliven Therapeutics Inc. (ELVN) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ELVN

• 4d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 29d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 37d
  SEC Form 4 filed by Collins Helen Louise

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 45d
  SEC Form 4 filed by Enliven Therapeutics Inc.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 46d
  CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 65d
  Director Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 65d
  CHIEF MEDICAL OFFICER Collins Helen Louise exercised 45,000 shares at a strike of $2.48 and sold $1,177,862 worth of shares (45,000 units at $26.17) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Kunkel Lori Anne

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Heyman Richard A.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Gupta Rishi

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Derynck Mika K

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Bauer Jake

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  SEC Form 4 filed by Director Ballal Rahul D.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  CHIEF OPERATING OFFICER Patel Anish was granted 20,000 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P was granted 18,750 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  CHIEF FINANCIAL OFFICER Hohl Benjamin was granted 25,000 shares, increasing direct ownership by 69% to 61,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 67d
  CHIEF MEDICAL OFFICER Collins Helen Louise was granted 25,000 shares (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 74d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $145,219 worth of shares (5,000 units at $29.04) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 93d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $535,099 worth of shares (20,000 units at $26.75) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 93d
  Director Heyman Richard A. sold $32,902 worth of shares (1,230 units at $26.75) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 102d
  CHIEF OPERATING OFFICER Patel Anish sold $1,351,762 worth of shares (48,300 units at $27.99) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 103d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $3,476,014 worth of shares (132,500 units at $26.23) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 103d
  Director Heyman Richard A. sold $348,281 worth of shares (13,920 units at $25.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 106d
  SEC Form 4 filed by Director Garland J. Scott

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 106d
  SEC Form 3 filed by new insider Garland J. Scott

  3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 123d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 13,000 shares at a strike of $2.48, increasing direct ownership by 57% to 36,000 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 123d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $84,206 worth of shares (5,000 units at $16.84) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 127d
  Director Kunkel Lori Anne exercised 15,958 shares at a strike of $1.12, increasing direct ownership by 108% to 30,712 units (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 134d
  SEC Form 4 filed by PRESIDENT AND CEO Fair Richard A.

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 134d
  SEC Form 3 filed by new insider Fair Richard A.

  3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 136d
  CHIEF OPERATING OFFICER Patel Anish sold $140,073 worth of shares (6,663 units at $21.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 155d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $279,155 worth of shares (12,500 units at $22.33) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 157d
  PRESIDENT AND CEO Kintz Samuel sold $272,739 worth of shares (12,500 units at $21.82) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 164d
  CHIEF OPERATING OFFICER Patel Anish sold $116,034 worth of shares (6,667 units at $17.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 185d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $276,025 worth of shares (12,500 units at $22.08) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 186d
  PRESIDENT AND CEO Kintz Samuel sold $266,654 worth of shares (12,500 units at $21.33) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 198d
  CHIEF OPERATING OFFICER Patel Anish sold $133,993 worth of shares (6,667 units at $20.10) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 206d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $66,291 worth of shares (3,250 units at $20.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 207d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $81,005 worth of shares (4,000 units at $20.25) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 207d
  PRESIDENT AND CEO Kintz Samuel sold $74,228 worth of shares (3,700 units at $20.06) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 212d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $30,045 worth of shares (1,500 units at $20.03) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 212d
  PRESIDENT AND CEO Kintz Samuel sold $56,084 worth of shares (2,800 units at $20.03) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 214d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $135,697 worth of shares (7,000 units at $19.39) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 218d
  PRESIDENT AND CEO Kintz Samuel sold $115,723 worth of shares (6,000 units at $19.29) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 227d
  CHIEF OPERATING OFFICER Patel Anish sold $134,957 worth of shares (6,667 units at $20.24) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 239d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $67,039 worth of shares (3,250 units at $20.63) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 247d
  Amendment: PRESIDENT AND CEO Kintz Samuel sold $30,343 worth of shares (1,517 units at $20.00) (SEC Form 4)

  4/A - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 247d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $248,216 worth of shares (12,500 units at $19.86) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 248d
  PRESIDENT AND CEO Kintz Samuel sold $219,906 worth of shares (10,983 units at $20.02) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 257d
  CHIEF OPERATING OFFICER Patel Anish sold $121,616 worth of shares (6,667 units at $18.24) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 269d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $66,504 worth of shares (3,250 units at $20.46) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 276d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $278,646 worth of shares (12,500 units at $22.29) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 278d
  PRESIDENT AND CEO Kintz Samuel sold $281,518 worth of shares (12,500 units at $22.52) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 285d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 1,000 shares at a strike of $2.48 and sold $22,655 worth of shares (1,000 units at $22.66) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 290d
  CHIEF OPERATING OFFICER Patel Anish sold $131,951 worth of shares (6,667 units at $19.79) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 298d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $67,956 worth of shares (3,250 units at $20.91) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 305d
  CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $267,458 worth of shares (12,500 units at $21.40) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 311d
  PRESIDENT AND CEO Kintz Samuel sold $277,292 worth of shares (12,500 units at $22.18) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
• 312d
  CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,000 shares at a strike of $2.48 and sold $67,655 worth of shares (3,000 units at $22.55) (SEC Form 4)

  4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)